Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:52:27.455Z.
Calculation as of: 2026-10-06T15:52:27.455Z.
Quote observation: 2026-10-06T15:49:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: be51af8dbdcf828107064bcf61af75d59853c311cbc38d104ed49a07c9c6f929
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.23B
Price/FCF Ratio
24.69
TTM Avg
2775.83
3Y Avg
1287.19
5Y Avg
1287.19
Market Cap
$1.22B
Price/FCF Ratio
24.13
TTM Avg
28.25
3Y Avg
29.31
5Y Avg
46.12
Market Cap
$1.22B
Price/FCF Ratio
N/A
TTM Avg
60.78
3Y Avg
115.25
5Y Avg
115.25
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ORIC Pharmaceuticals, Inc. (ORIC) | $1.24B | N/A | N/A | N/A | N/A |
| Omada Health (OMDA)vs › | $1.23B | 61.32 | 62.80 | 62.80 | 62.80 |
| Cronos Group Inc. (CRON)vs › | $1.23B | 24.69 | 2775.83 | 1287.19 | 1287.19 |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 24.13 | 28.25 | 29.31 | 46.12 |
| MannKind Corporation (MNKD)vs › | $1.22B | N/A | 60.78 | 115.25 | 115.25 |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.16B | N/A | 9.27 | 9.27 | 9.27 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 7.92 | 9.04 | 20.26 | 32.54 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
